Protocol Ledger

NCT04417036 · Phase II · TERMINATED

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the

Interventional Phase II clinical trial protocol NCT04417036 sponsored by Bayer in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-07 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04417036
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04417036
Protocol FieldVerified Registry Value
NCT IdentifierNCT04417036
Consolidated Lead SponsorBayer
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2020-07-07
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04417036
Hospital Research SiteLocationSite Profile
Fakultni nemocnice Kralovske VinohradyPrague, CzechiaOpen Hospital Dossier ->
Fakultni nemocnice v MotolePrague, CzechiaOpen Hospital Dossier ->
Fondazione IRCCS CA' Granda Ospedale Maggiore PoliclinicoMilan, ItalyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI